» Articles » PMID: 38622332

Could Pan-Immune-Inflammation Value Be a Marker for the Diagnosis of Coronary Slow Flow Phenomenon?

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation plays a key role in the pathogenesis of the coronary slow flow phenomenon (CSFP). The newly developed inflammatory marker, pan-immune-inflammation value (PIV), is associated with adverse cardiovascular events. This study investigated the predictive value of PIV for diagnosing CSFP in comparison to other inflammation-based markers. A total of 214 patients, 109 in the CSFP group and 105 in the normal coronary flow (NCF) group, were retrospectively included in the study. Coronary flow was calculated using the Thrombolysis in Myocardial Infarction frame count method. In addition to PIV, other inflammatory markers such as neutrophil-lymphocyte ratio, platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated for the patients. The average age of patients was 50.3 ± 8.4, with a male ratio of 55.1%. Compared to the NCF group, patients in the CSFP group had higher levels of hyperlipidemia, glucose, triglyceride, NLR, PLR, SII, and PIV, while their high-density lipoprotein cholesterol (HDL-C), was lower (p < 0.05). Logistic regression analysis demonstrated that HDL-C, glucose, triglyceride, and PIV were independent predictor factors for CSFP (p < 0.05). PIV is a strong and independent predictor factor for CSFP and superior in predicting CSFP compared to other inflammatory markers.

Citing Articles

The Global Immune-Nutrition Inflammation Index for Predicting Coronary Slow Flow Phenomenon in Patients with Angina and No Obstructive Coronary Arteries.

Guo J, Xiang Z, Ma D Int J Gen Med. 2025; 18:1325-1332.

PMID: 40070680 PMC: 11895676. DOI: 10.2147/IJGM.S516108.


The progression of non-culprit coronary lesion is related to higher SII, SIRI, and PIV in patients with ACS.

Yilu Z, Zhanglong W, Fanke H, Jing G, Yue W, Yuwen C Medicine (Baltimore). 2025; 103(52):e41094.

PMID: 39969298 PMC: 11688051. DOI: 10.1097/MD.0000000000041094.


The Predictive Value of Pan-Immune-Inflammation Value for Saphenous Vein Graft Disease in Post-Coronary Artery Bypass Grafting Patients.

Serhatlioglu F, Cetinkaya Z, Yilmaz Y J Cardiovasc Dev Dis. 2024; 11(11).

PMID: 39590180 PMC: 11594304. DOI: 10.3390/jcdd11110337.


Association between inflammatory burden index and coronary slow flow phenomenon in patients with chest pain and no obstructive coronary arteries.

Wen Z, Long J, Wang Y BMC Cardiovasc Disord. 2024; 24(1):595.

PMID: 39462315 PMC: 11515272. DOI: 10.1186/s12872-024-04281-4.


Prognostic value of pan immune-inflammation value in patients undergoing unprotected left main coronary artery stenting.

Karaduman A, Yilmaz C, Keten M, Balaban I, Kultursay B, Danisman N Biomark Med. 2024; 18(21-22):957-967.

PMID: 39431313 PMC: 11633389. DOI: 10.1080/17520363.2024.2412515.


References
1.
Tambe A, Demany M, ZIMMERMAN H, Mascarenhas E . Angina pectoris and slow flow velocity of dye in coronary arteries--a new angiographic finding. Am Heart J. 1972; 84(1):66-71. DOI: 10.1016/0002-8703(72)90307-9. View

2.
Monteiro Junior J, Torres D, Sobral Filho D . Hematological Parameters as Prognostic Biomarkers in Patients with Cardiovascular Diseases. Curr Cardiol Rev. 2019; 15(4):274-282. PMC: 6823671. DOI: 10.2174/1573403X15666190225123544. View

3.
Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G . Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2012; 11(1):55-9. DOI: 10.1586/erc.12.159. View

4.
Ruparelia N, Chai J, Fisher E, Choudhury R . Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2016; 14(3):133-144. PMC: 5525550. DOI: 10.1038/nrcardio.2016.185. View

5.
Vehkavaara S, Seppala-Lindroos A, Westerbacka J, Groop P, Yki-Jarvinen H . In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care. 1999; 22(12):2055-60. DOI: 10.2337/diacare.22.12.2055. View